A5044858619- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Education
- Eating Disorders and Behaviors
- Diet and metabolism studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Metabolism, Diabetes, and Cancer
- Mobile Health and mHealth Applications
- Bariatric Surgery and Outcomes
- Cardiovascular Function and Risk Factors
- Child Nutrition and Feeding Issues
- Obesity, Physical Activity, Diet
- Pharmacology and Obesity Treatment
- Heart Rate Variability and Autonomic Control
- Ovarian function and disorders
- Botulinum Toxin and Related Neurological Disorders
- Health, Medicine and Society
- Muscle metabolism and nutrition
- Gestational Diabetes Research and Management
- Pituitary Gland Disorders and Treatments
- Chronic Disease Management Strategies
- Cardiac pacing and defibrillation studies
Université de Montpellier
2016-2025
Inserm
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Centre Hospitalier Universitaire de Montpellier
2016-2025
Institut de Génomique Fonctionnelle
2015-2025
Centre Hospitalier Universitaire de Grenoble
2024
Hôpital d'Hautepierre
2024
Université de Limoges
2024
Hôpital Lapeyronie
2013-2023
Capital Region of Denmark
2022-2023
Diabetes and Covid-19 is associated with an increased risk of severe Covid-19. New-onset diabetes metabolic complications preexisting diabetes, including diabetic ketoacidosis h...
A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.
To define the threshold for excess glucose variability (GV), one of main features dysglycemia in diabetes.A total 376 persons with diabetes investigated at University Hospital Montpellier (Montpellier, France) underwent continuous monitoring. Participants type 2 were divided into several groups-groups 1, 2a, 2b, and 3 (n = 82, 28, 65, 79, respectively)-according to treatment: 1) diet and/or insulin sensitizers alone; 2) oral therapy including an insulinotropic agent, dipeptidyl peptidase 4...
Integrated closed-loop control (CLC), combining continuous glucose monitoring (CGM) with insulin pump (continuous subcutaneous infusion [CSII]), known as artificial pancreas, can help optimize glycemic in diabetes. We present a fundamental modular concept for CLC design, illustrated by clinical studies involving 11 adolescents and 27 adults at the Universities of Virginia, Padova, Montpellier. tested two constructs: standard to range (sCTR), designed augment plus CGM preventing extreme...
Abstract The significant and growing global prevalence of diabetes continues to challenge people with (PwD), healthcare providers, payers. While maintaining near-normal glucose levels has been shown prevent or delay the progression long-term complications diabetes, a proportion PwD are not attaining their glycemic goals. During past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials real-world studies that use AID...
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders cancers, which together are the predominant problem of 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care multi-scale, multi-modal multi-level systems approaches tackle NCDs as a common group diseases. Rather than studying each...
With the use of digital genetic amplifiers and logic gates, prototype whole-cell biosensors can be engineered to detect diagnostic biomarkers in complex human clinical samples.
BackgroundClosed-loop insulin delivery systems are expected to become a standard treatment for patients with type 1 diabetes. We aimed assess whether the Diabeloop Generation (DBLG1) hybrid closed-loop artificial pancreas system improved glucose control compared sensor-assisted pump therapy.MethodsIn this multicentre, open-label, randomised, crossover trial, we recruited adults (aged ≥18 years) at least 2 year history of diabetes, who had been treated external therapy 6 months, glycated...
OBJECTIVE To compare the improvements in glycemic control associated with transitioning to insulin pump therapy patients using continuous glucose monitoring versus standard blood self-monitoring. RESEARCH DESIGN AND METHODS The RealTrend study was a 6-month, randomized, parallel-group, two-arm, open-label of 132 adults and children uncontrolled type 1 diabetes (A1C ≥8%) being treated multiple daily injections. One group fitted Medtronic MiniMed Paradigm REAL-Time system (PRT group), an...
In 2008-2009, the first multinational study was completed comparing closed-loop control (artificial pancreas) to state-of-the-art open-loop therapy in adults with type 1 diabetes mellitus (T1DM).The design of algorithm done entirely silico, i.e., using computer simulation experiments N=300 synthetic "subjects" T1DM instead traditional animal trials. The clinical recruited 20 at Universities Virginia (11); Padova, Italy (6); and Montpellier, France (3). Open-loop admission scheduled 3-4 weeks...
OBJECTIVE To evaluate the feasibility of a wearable artificial pancreas system, Diabetes Assistant (DiAs), which uses smart phone as closed-loop control platform. RESEARCH DESIGN AND METHODS Twenty patients with type 1 diabetes were enrolled at Universities Padova, Montpellier, and Virginia Sansum Research Institute. Each trial continued for 42 h. The United States studies conducted entirely in outpatient setting (e.g., hotel or guest house); Italy France hybrid hospital–hotel admissions. A...
OBJECTIVE We estimate the effect size of hypoglycemia risk reduction on closed-loop control (CLC) versus open-loop (OL) sensor-augmented insulin pump therapy in supervised outpatient setting. RESEARCH DESIGN AND METHODS Twenty patients with type 1 diabetes initiated study at Universities Virginia, Padova, and Montpellier Sansum Diabetes Research Institute; 18 completed entire protocol. Each patient participated two 40-h sessions, CLC OL, randomized order. Sensor (Dexcom G4) (Tandem t:slim)...
Modularity plays a key role in many engineering systems, allowing for plug-and-play integration of components, enhancing flexibility and adaptability, facilitating standardization. In the control diabetes, i.e., so-called "artificial pancreas," modularity allows step-wise introduction (and regulatory approval for) algorithmic starting with subsystems assured patient safety followed by higher layer components that serve to modify patient's basal rate real time. this paper, we introduce...
OBJECTIVE Attempts to build an artificial pancreas by using subcutaneous insulin delivery from a portable pump guided glucose sensor have encountered delays and variability of absorption. We tested closed-loop intraperitoneal infusion implanted driven via proportional-integral-derivative (PID) algorithm. RESEARCH DESIGN AND METHODS Two-day therapy (except for 15-min premeal manual bolus) was compared with 1-day control phase open-loop delivery, according randomized order, in hospital setting...